[클리니컬 히스토리] JW중외제약, 中 비만치료제 도입…대사질환 확장

JW Pharmaceutical's in-licensing of a late-stage GLP-1 agonist demonstrates a strategic pivot toward acquiring proven assets rather than developing from scratch, enabling faster entry into the booming obesity treatment market. Success hinges not on the drug's convenience features alone, but on Phase 3 clinical efficacy, safety management, and pricing strategies that convince patients and providers of its value proposition. This exemplifies broader pharma industry trends of prioritizing speed-to-market and cost efficiency over traditional long-term R&D models in high-growth therapeutic areas.